Skip to content

The effect of Naikan cognitive therapy on depression, anxiety, and inflammatory factor levels

The effect of Naikan cognitive therapy on depression, anxiety, and inflammatory factor levels

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300076344
Enrollment
Unknown
Registered
2023-10-05
Start date
2023-08-01
Completion date
Unknown
Last updated
2024-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depressive disorder, generalized anxiety disorder

Interventions

Vipassana cognitive therapy intervention group (NCT group):Participants were treated with Vipassana cognitive therapy and the intervention consisted of two components: Vipassana therapy (5 days) and c
General supportive care group (GST group):This includes lectures on emotional disorders and opportunities for participants to share their psychological distress and receive appropriate psychological s

Sponsors

Tianjin Beichen Anjin Hospital/ Department of Mental Health and Psychology, School of Basic Medical Sciences, Tianjin Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1) Adult patients between the ages of 18-65 years. 2) In the past month, I have reported anxiety or depression. 3) Have good Chinese understanding skills and be willing to participate in research and sign informed consent.

Exclusion criteria

Exclusion criteria: 1) Those currently receiving antipsychotic drugs. 2) Currently receiving psychotherapy or counseling. 3) Previous Vipassana cognitive therapy treatment. 4) Severe mental or physical illness, including the following: a) Currently clinically diagnosed with any mental disorder (except depression, anxiety disorder). b) Have been clinically diagnosed with a serious psychiatric illness. c) A first-degree relative who has been or has previously been diagnosed with schizophrenia. d) Have a history of addictive substance abuse. e) Currently or previously clinically diagnosed with a severe musculoskeletal, digestive, respiratory, urinary, reproductive, endocrine, immune, or circulatory disease (severe disease is defined as a disease that meets any of the following criteria: (1) is likely to threaten the subject's life at any time or seriously threaten the participant's health for a short period of time; (2) the subject needs to use drug treatment that may affect mental state; (3) diseases that may hinder the completion of the entire research process).

Design outcomes

Primary

MeasureTime frame
Interleukin—6;Interleukin—1ß;C-reaction protein;

Secondary

MeasureTime frame
Beck Depression Inventory, BDI;Beck Anxiety Inventory, BAI;Well-being score;

Countries

China

Contacts

Public ContactFuqiang Mao

Department of Mental Health and Psychology, School of Basic Medical Sciences, Tianjin Medical University

maofq@tmu.edu.cn+86 137 0216 0048

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026